Corticosteroids in Myositis and Scleroderma

Rheumatic Disease Clinics of North America

Volumn 42, Issue 1, 2016, Pages 103-

  Postolova, Anna ^a   Chen, Jennifer K ^b   Chung, Lorinda ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Corticosteroids; Glucocorticoids; Idiopathic inflammatory myopathies; Morphea; Myositis; Scleroderma; Systemic sclerosis

Indexed keywords

ABATACEPT; AZATHIOPRINE; BETAMETHASONE; BOSENTAN; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DESONIDE; DEXAMETHASONE; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMATINIB; IMIQUIMOD; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PENICILLIN DERIVATIVE; PREDNISONE; RITUXIMAB; TACROLIMUS; TRIAMCINOLONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG POTENCY; ELECTROMYOGRAPHY; HUMAN; IMMUNE MEDIATED NECROTIZING MYOPATHY; INCLUSION BODY MYOSITIS; INTERSTITIAL LUNG DISEASE; MONOTHERAPY; MORPHEA; MUSCLE BIOPSY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMYOSITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS; TREATMENT PLANNING; BIOPSY; MYOSITIS, INCLUSION BODY; PATHOLOGY; SCLERODERMA, SYSTEMIC; SKELETAL MUSCLE; SKIN;

ADRENAL CORTEX HORMONES; BIOPSY; DERMATOMYOSITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCLE, SKELETAL; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84999040361     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.08.011     Document Type: Review

References (56)

1. Ernste F.C., Reed A.M. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013, 88:83-105.
2. Mammen A.L. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011, 7:343-354.
3. Findlay A.R., Goyal N.A., Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve 2015, 51(5):638-656.
4. Bohan A., Peter J.B., Bowman R.L., et al. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977, 86:255-286.
5. Tjarnlund A, Bottai M, Rider LG, et al. Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Washington, DC: ACR Annual Meeting. 2012. Abstract.
6. Dimachkie M.M., Barohn R.J., Amato A.A. Idiopathic inflammatory myopathies. Neurol Clin 2014, 32:595-628.
7. Femia A.N., Vleugels R.A., Callen J.P. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol 2013, 14:291-313.
8. Strowd L.C., Jorizzo J.L. Review of dermatomyositis: establishing the diagnosis and treatment algorithm. J Dermatolog Treat 2013, 24:418-421.
9. Miller S.A., Glassberg M.K., Ascherman D.P. Pulmonary complications of inflammatory myopathy. Rheum Dis Clin North Am 2015, 41:249-262.
10. Tansley S.L., Betteridge Z.E., McHugh N.J. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol 2013, 25:772-777.
11. Sarkar K., Miller F. Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies. Autoimmunity 2004, 37:291-294.
12. Winkelmann R.K., Mulder D.W., Lambert E.H., et al. Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients. Mayo Clin Proc 1968, 43:545-556.
13. Lundberg I., Kratz A.K., Alexanderson H., et al. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000, 43:336-348.
14. van de Vlekkert J., Hoogendijk J.E., de Haan R.J., et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 2010, 20:382-389.
15. Oddis C.V., Reed A.M., Aggarwal R., et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013, 65:314-324.
16. Euwer R.L., Sontheimer R.D. Amyopathic dermatomyositis (dermatomyositis sine myositis) presentation of six new cases and review of the literature. J Am Acad Dermatol 1991, 24:959-966.
17. Ghirardello A., Borella E., Beggio M., et al. Myositis autoantibodies and clinical phenotype. Auto Immun Highlights 2014, 5:69-75.
18. Gil B., Merav L., Pnina L., et al. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol 2015, [Epub ahead of print].
19. Drake L.A., Dinehart S.M., Farmer E.R., et al. Guidelines of care for dermatomyositis. American Academy Dermatology. J Am Acad Dermatol 1996, 34:824-829.
20. Pelle M.T., Callen J.P. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with lupus erythematosus. Arch Dermatol 2002, 138:1231-1233.
21. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
22. Schmidt J., Dalakas M.C. Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. Expert Rev Clin Immunol 2013, 9:1125-1133.
23. Griggs R.C., Askanas V., DiMauro S., et al. Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
24. Amato A.A., Barohn R.J. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009, 80:1186-1193.
25. Breithaupt M., Schmidt J. Update on treatment of inclusion body myositis. Curr Rheumatol Rep 2013, 15:329.
26. Quinn C., Salameh J.S., Smith T., et al. Necrotizing myopathies: an update. J Clin Neuromuscul Dis 2015, 16:131-140.
27. Hoogendijk J.E., Amato A.A., Lecky B.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis. Neuromuscul Disord 2004, 14:337-345.
28. Christopher-Stine L., Casciola-Rosen L.A., Hong G., et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010, 62:2757-2766.
29. Grable-Esposito P., Katzberg H.D., Greenberg S.A., et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185-190.
30. Barsotti S., Bellando Randone S., Guiducci S., et al. Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol 2014, 32:S194-S205.
31. Nashel J., Steen V. Scleroderma mimics. Curr Rheumatol Rep 2012, 14:39-46.
32. Kayser C., Fritzler M.J. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol 2015, 15:167.
33. Laxer R.M., Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006, 18:606-613.
34. Fett N., Werth V.P. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011, 64:217-228.
35. Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol 2013, 31:432-437.
36. Christen-Zaech S., Hakim M.D., Afsar F.S., et al. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol 2008, 59:385-396.
37. Nagai Y., Hattori T., Ishikawa O. Unilateral generalized morphea in childhood. J Dermatol 2002, 29:435-438.
38. Dytoc M.T., Kossintseva I., Ting P.T. First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol 2007, 157:615-618.
39. Unterberger I., Trinka E., Engelhardt K., et al. Linear scleroderma "en coup de sabre" coexisting with plaque-morphea: neuroradiological manifestation and response to corticosteroids. J Neurol Neurosurg Psychiatry 2003, 74:661-664.
40. Zwischenberger B.A., Jacobe H.T. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 2011, 65:925-941.
41. Zulian F., Martini G., Vallongo C., et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2011, 63:1998-2006.
42. Torok K.S., Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol 2012, 39:286-294.
43. Joly P., Bamberger N., Crickx B., et al. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 1994, 130:663-664.
44. Fett N., Werth V.P. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011, 64:231-242.
45. Stausbol-Gron B., Olesen A.B., Deleuran B., et al. Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases. Acta Derm Venereol 2011, 91:686-688.
46. van den Hoogen F., Khanna D., Fransen J., et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013, 65:2737-2747.
47. Poormoghim H., Lucas M., Fertig N., et al. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000, 43:444-451.
48. Walker U.A., Tyndall A., Czirjak L., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research Group database. Ann Rheum Dis 2007, 66:754-763.
49. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
50. Shah A.A., Wigley F.M. My approach to the treatment of scleroderma. Mayo Clin Proc 2013, 88:377-393.
51. McMahan Z.H., Hunners L.K. Systemic sclerosis-challenges for clinical practice. Nat Rev Rheumatol 2013, 9:90-100.
52. Steen V.D. Kidney involvement in systemic sclerosis. Presse Med 2014, 43:e305-e314.
53. Hunzelmann N., Moinzadeh P., Genth E., et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009, 11:R30.
54. Wells A.U., Margaritopoulos G.A., Antoniou K.M., et al. Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med 2014, 35:213-221.
55. Schoenfeld S.R., Castelino F.V. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2015, 41:237-248.
56. Tashkin D.P., Elashoff R., Clements P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.